Comparative Pharmacology
Head-to-head clinical analysis: PROAIR DIGIHALER versus PROAIR RESPICLICK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROAIR DIGIHALER versus PROAIR RESPICLICK.
PROAIR DIGIHALER vs PROAIR RESPICLICK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, resulting in bronchodilation.
Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.
90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.
Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
None Documented
None Documented
Terminal elimination half-life of albuterol (active ingredient) is 3.8-5.0 hours; clinical context indicates drug is rapidly cleared with no significant accumulation
Terminal elimination half-life is 3–4 hours for inhaled albuterol; systemic half-life after inhalation is approximately 3.8 hours, supporting q4-6h dosing.
Renal: 60-70% of systemically absorbed dose excreted in urine as sulfate conjugate; biliary/fecal: minimal (approximately 10% unchanged); unchanged drug in urine: <2%
Primarily renal (60–70% as unchanged drug and metabolites, mainly as 4'-O-sulfate ester); biliary/fecal excretion accounts for <20%.
Category C
Category C
Beta-2 Agonist Bronchodilator
Beta-2 Agonist Bronchodilator